SNN: A Potential Drug Target and Biomarker for Neurological Disorders

Target Name: SNN

NCBI ID: G8303

Content of Review Report on SNN Target / Biomarker

SNN

Other Name(s): Stannin | AG8_1 | stannin | SNN_HUMAN

SNN: A Potential Drug Target and Biomarker for Neurological Disorders

SNN, or Sodium-Glucose cotransporter 2, is a protein that is expressed in the brain and plays a crucial role in the regulation of sodium and glucose levels in the body. It is also involved in the transport of other molecules, including amino acids, creatine, and nucleotides.

Recent studies have identified SNN as a potential drug target and biomarker for a variety of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression.

One of the reasons for the interest in SNN is its role in the regulation of sodium and glucose levels. Disruptions in these levels can have serious consequences for the brain, including the development of neurodegenerative diseases. Studies have shown that SNN plays a critical role in the regulation of sodium and glucose levels in the brain, and that it is involved in the development and progression of these conditions.

In addition to its role in the regulation of sodium and glucose levels, SNN is also involved in the transport of other molecules that are important for brain function. For example, it has been shown to play a role in the transport of amino acids, which are essential for the development and maintenance of neural tissue, as well as the transport of creatine, which is involved in the production of energy in the brain.

Another promising aspect of SNN is its potential as a drug target is its role in the regulation of pain. Studies have shown that SNN is involved in the regulation of pain perception and that it plays a role in the development of chronic pain conditions.

In addition to its potential as a drug target and biomarker, SNN has also been shown to have potential therapeutic applications in a variety of other fields. For example, it has been shown to have potential as a treatment for neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Studies have shown that SNN can be used to treat these conditions by modulating the levels of sodium and glucose in the brain, which can help to prevent the development and progression of these conditions.

Overall, SNN is a protein that has the potential to be a drug target and biomarker for a variety of neurological and psychiatric disorders. Studies are continuing to investigate its role in the regulation of sodium and glucose levels in the brain, as well as its potential as a treatment for pain and other conditions. As research continues, SNN is likely to become an increasingly important protein in the study of neurological and psychiatric disorders.

Protein Name: Stannin

Functions: Plays a role in the toxic effects of organotins (PubMed:15269288). Plays a role in endosomal maturation (PubMed:27015288)

The "SNN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets